The role of CD36 receptor in the pathogenesis of atherosclerosis

Area of Science:

• Cardiovascular Research
• Immunology
• Molecular Biology

Background:

• Atherosclerosis involves chronic inflammation in artery walls, with oxidized low-density lipoproteins (ox-LDL) driving plaque formation.
• Macrophages internalize ox-LDL primarily via scavenger receptors, with CD36 identified as a key player.
• Previous research indicated CD36's significant role in atherosclerosis development.

Purpose of the Study:

• To review the multifaceted role of the CD36 receptor in atherosclerosis.
• To discuss the implications of CD36 expression levels in human cardiovascular disease.
• To explore therapeutic strategies targeting CD36, including potential benefits and risks.

Main Methods:

• Literature review of animal and human studies on CD36 and atherosclerosis.
• Analysis of data linking CD36 expression to atherosclerotic plaque development and coronary heart disease incidence.
• Examination of research on pharmacological interventions affecting CD36.

Main Results:

• Animal models demonstrate CD36 deficiency prevents atherosclerosis, even with atherogenic diets.
• Human autopsy studies reveal increased CD36 expression on macrophages in atherosclerotic plaques of obese patients.
• Contrasting findings show increased coronary heart disease in patients with decreased CD36 expression, challenging its established role.

Conclusions:

• The role of CD36 in human atherosclerosis is complex and warrants further investigation.
• Therapeutic targeting of CD36 may offer benefits but requires careful consideration of potential adverse effects.
• Understanding CD36's dual role is crucial for developing effective atherosclerosis treatments.